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Abstract 
We hypothesise that the NRF2 transcription factor would act a biomarker of poor prognosis in 
colorectal cancer. We derived and validated an mRNA based metagene signature of NRF2 sig- 
nalling and validated it in 1360 patients from 4 different datasets as an independent biomarker of 
poor prognosis. This is a novel insight into the molecular signalling of colorectal cancer. 
Background: NRF2 over activity confers poor prognosis in some cancers but its prognostic role 
in colorectal cancer (CRC) is unknown. As a transcription factor, we hypothesise a signature of 
NRF2 regulated genes could act as a prognostic biomarker in CRC and reveal novel biological 
insights. 
Methods: Using known NRF2 regulated genes, differentially expressed in CRC, we defined a 
signature of NRF2 pathway activity using principal component analysis and Cox proportional 
hazard models and tested it in four independent mRNA datasets, profiled on three different mRNA 
platforms. 
Results: 36 genes comprised the final NRF2 signature. 1360 patients were included in the vali- 
dation. High NRF2 was associated with worse disease free survival (DFS) and/or overall survival 
(OS) in all datasets: (GSE14333 HR = 1.55, 95% C.I 1.2–2.004, p = 0.0008; GSE39582 HR = 1.24, 
95% C.I 1.086–1.416, p = 0.001; GSE87211 HR = 1.431, 95% C.I 1.06–1.93, p = 0.056; MRC 
FOCUS trial HR = 1.14, 95% C.I 1.04–1.26, p = 0.008). In multivariate analyses, NRF2 remained 
significant when adjusted for stage and adjuvant chemotherapy in stage I-III disease, and BRAF 
V600E mutation and sidedness in stage IV disease. NRF2 activity was particular ly enr iched in 
Consensus Molecular Subtype (CMS) 4. 
Conclusion: For the first time, NRF2 is shown to be a consistent, robust prognostic biomarker 
across all stages of colorectal cancer with additional clinical value to current known prognostic 
biomarkers. High NRF2 signalling in CMS 4 further refines the molecular taxonomy of CRC, a 
new biological insight, suggesting avenues of further study. 
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1 Here, we define the X major PCs as the X most variable PCs that Background 
Colorectal cancer (CRC) is the 4th most common cancer in 
the UK with 41,700 new cases per annum and only 57% 
of patients will live ten years or more [1] . An improved un- 
derstanding of the biology of colorectal cancer may provide 
the basis for stratification of patients for differing treatment 
programmes, first by identifying prognostic effects. Current, 
known prognostic factors include ‘sidedness’ (left or right side 
of the colon) [2] —which is assumed to be surrogate of tumour 
[3] and patient biology [4] —RAS mutant status, BRAF status 
[5] and mismatch repair status [ 6 , 7 ]. The most widely used, 
RNA expression based classifier is the Consensus Molecu- 
lar Subtype (CMS) [8] . It highlights that colorectal cancer is a 
significantly heterogeneous disease with different prognostic 
expectations among four subgroups. The taxonomy applied to 
each of the four subtypes indicate enriched pathways, but no 
subtype is defined by individual events, genetic aberrations 
or expression pathways. Therefore, there may be additional, 
heretofore unknown biological pathways that contribute to the 
prognostic differences between the subtypes. 
The KEAP1-NRF2 pathway is an canonical signalling path- 
way which has been implicated in all the Hallmarks of Cancer 
[9] . Though of prognostic importance in many tumours types, 
notably lung cancer [10] , its significance in CRC is unknown. 
NRF2 is a potent transcriptional activator that plays a cen- 
tral role in cell protection against oxidative and electrophilic 
stress. NRF2 activity is tightly regulated by KEAP1. Under 
basal (unstressed) conditions KEAP1, part of the Cul3 ubiqui- 
tin ligase family, mediates polyubiquitination and proteasomal 
degradation of NRF2 protein [11] . Cellular stresses modify 
the structural integrity KEAP1-CUL3 ligase complex resulting 
in declining ubiquitination activity and an increase in cellular 
NRF2. Unbound NRF2 translocates to the nucleus and binds 
to antioxidant response element (ARE) sequences to regu- 
late the transcription of suites of genes, including intracellu- 
lar redox control, metabolic pathways, autophagy and drug 
transport [12] . Historically the NRF2 pathway was deemed 
to function in ‘tumour suppressor’ like capacity, allowing the 
cell to defend against stressors such as carcinogens [12] . Re- 
cent evidence shows that some tumours acquire constitutive 
activation of the pathway which allow it to function in an ‘onco- 
gene’ like fashion, promoting cell survival, resisting radiation, 
chemotherapeutics and dysregulating metabolism [ 13 , 14 ]. 
There are a number of distinct mechanisms by which the 
NRF2 pathway can become constitutively activated in CRC 
[15] . Mutations in both KEAP1 and NFE2L2 have been de- 
scribed in a up to 7.8% of colorectal cancers [16] , although 
the rate in TCGA is less than 2.4% and 0.9% respectively [17] . 
However, the level of NRF2 signalling in the TCGA dataset is 
higher than expected for the low somatic mutation rate ob- 
served [18] , suggesting complex post transcriptional mecha- 
nisms of activation. Epigenetic modifications, methylation, of 
KEAP 1 in CRC silencing its ability to regulate NRF2 [19] and 
direct activation of NRF2 transcription via oncogenes KRAS 
G12D 
, BRAF V619E and c-MYC ERT2 have all been described 
[20] . 
It is unlikely that NFE2L2 (the gene encoding NRF2 pro- 
tein) mutation or expression in isolation will capture the full 
effect of pathway activity, and prove a useful biomarker. How- 
ever, as NRF2 functions as a transcription factor controlling e known suite of antioxidant response element (ARE) regu- 
ated genes, we hypothesise that a ‘signature’ of NRF2 activ- 
ty, could be used to aggregate different mechanisms of path- 
ay activity and act as a biomarker of prognosis in CRC. Here, 
e define a signature of NRF2 activity as ‘a metagene which is 
 set of known NRF2 targets with coordinated mRNA expres- 
ion representing the component of NRF2 pathway potentially 
elevant to prognostic prediction’. We detail the derivation of 
n NRF2 signature from RNA expression data using a can- 
idate gene approach [21] in colorectal cancer datasets and 
emonstrate, for the first time, that high NRF2 activity is a 
iomarker of poor prognosis across all stages of CRC. 
ethods 
andidate gene selection 
nown NRF2 regulated genes were selected from two pub- 
ished prognostic lung cancer signatures [ 22 , 23 ] and refined 
or differential expression using the Oncomine database [24] . 
nput parameters “Cancer Type” and “Analysis Type” were set 
o ‘colorectal cancer and ‘cancer versus normal’ respectively. 
ifferential expression was determined by threshold values of 
old change > 2, p-value < 0.0001 and gene rank of top 10%. 
he database normalises gene expression across all selected 
atasets to allow summative gene expression comparisons. 
he resulting median gene rank for the meta-analysis across 
ll selected datasets was calculated with its associated p- 
alue, which was corrected for multiple hypothesis testing us- 
ng the false discovery rate method [25] . 
onstruction of the signature of NRF2 
rincipal component analysis (PCA) was applied to all probes 
epresenting the candidate NRF2 target genes. This gener- 
ted a new set of continuous var iables, pr incipal components 
PCs), which were weighted averages of the RNA expressions 
cross the probes considered. 
Supervised variable selection was performed to decide 
ow many major PCs 1 would be useful for predicting progno- 
is in the training set. A Cox proportional hazard regression 
odel was used to model the prognosis predicted by the PCs 
f NRF2 activity. 
The NRF2 activity in each validation set was obtained by 
erforming PCA on the corresponding probe sets (see sup- 
lementary figure 1 and supplementary information for further 
etails). 
atasets 
ublically available colorectal datasets were downloaded 
rom the Gene Expression Omnibus (GEO) database, ac- 
essed from the R programming environment using the 
ackages ‘GEOquery’ [26] and ‘Biobase’ [27] obtained from 
ttps://bioconductor.org/biocLite.R. All datasets are sum- 
arised in Table 1 . The datasets were divided into a train- xplains 80% of the variation in the data. 
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Table 1 Cohort characteristics of the training and validation sets. 
GSE17536 
(Training set) GSE14333 GSE39582 MRC FOCUS trial GSE87211 
Patients 177 226 570 375 (355 DNA 
mutant status) 
189 
Tissue type Fresh frozen Fresh frozen Fresh frozen FFPE Fresh frozen 
Platform array Affymetrix 
U133 v2.0 
Affymetrix 
U133 v2.0 
Affymetrix U133 
v2.0 
Affymetrix Xcel Agilent Human 
4 × 44k v2 
Primary site Colon Colorectal Colon Colon Rectum 
Stage I 24 (13.6%) 41 (18%) 37 (6.5%) 
II 57 (32.2%) 95 (42%) 267 (47%) 70 (30.8%) 
III 57 (32.2%) 93 (41%) 206 (36%) 143 (63%) 
IV 39 (22%) 60 (10.5%) 375 (100%) 14 (6.2%) 
Outcome variable OS DFS DFS OS OS DFS OS 
Covariates 
Chemo(radio)therapy Yes 72 Yes 240 375 (100%) 189 (100%) 
No 154 No 326 
Site of primary Prox. 232 Left 203 
Dist. 351 Right 152 
BRAF V600E mutation Mut 51 38 (10%) 
Mismatch Repair status dMMR 77 dMMR 15 
pMMR 459 pMMR 326 
The numbers of cases, type of tissue, RNA expression platform, outcome variable and available covariates for adjusted analyses are indicated. 
(DFS = Disease Free Survival, OS = Overall survival, dMMR = deficient Mismatch repair, pMMR = proficient Mismatch Repair). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ing set, GSE17536 [28] , and validation sets. Validation was
carried out using datasets representative of non-metastatic,
stage I–III disease (GSE14333 and GSE39582) [ 29 , 30 ],
metastatic disease (MRC FOCUS trial) [31] and rectal only
cancer (GSE87211) [32] . As part of the Stratification in Col-
orectal cancer (S:CORT) consortium, we had access to the
MRC FOCUS trial data including the RNA expression pro-
files generated by S:CORT (See supplementary information).
GSE17536, GSE14333, GSE39582 were profiled using the
Affymetrix U133 Plus 2.0 array, GSE87211 used the Agilent-
026652 Whole Human Genome Microarray 4 × 44 K v2 and
the MRC FOCUS trial used the Affymetrix Xcel TM array. 
Statistical analysis 
Primary analysis 
The primary analysis for each validation set was to deter-
mine whether the NRF2 activity has a prognostic effect on
disease free survival (DFS) and/or overall survival (OS) by
a Cox regression model with NRF2 activity as the only co-
variate. The likelihood ratio test (LRT) was used to quantify
evidence against that NRF2 activity provides no explanatory
power. For the construction of Kaplan-Meier (K-M) curves,
NRF2 activity was subdivided by tertiles. Hazard ratios, and
confidence intervals, presented for these curves are between
the upper and lower tertiles. 
Secondary analyses 
To assess whether the prognostic effect of the NRF2 activ-
ity was confounded by other known prognostic variables we
performed adjusted analyses using multivariate Cox PH re-gression models. Because adjusting variables varied across
datasets, no adjusting variables were used in the training set.
A LRT was performed to quantify the evidence against NRF2
activity provides no explanatory power in addition to the ad-
justing variables. The adjusting variables used for the sec-
ondary analyses are summarised in Table 1 . All statistical
analyses were conducted using R [33] . 
Results 
NRF2 signature derivation and training 
In total 62 candidate genes were analysed in 9 independent
colorectal datasets for differential expression relative to nor-
mal tissue [ 17 , 34–39 ]. Some datasets were subsetted into
different anatomical sites for the purposes of analysis result-
ing in 24 discrete sets of data (see supplementary Table 1).
40 were found to be differentially expressed in tumours, 21 of
which were significantly over-expressed and 20 which were
significantly under-expressed, in at least one or more of the
datasets (supplementary Figure 1). One gene, COL3A1, was
shared as it was over expressed in some datasets and under
expressed in others. Of the 40 differentially expressed genes,
four could not be matched between the training and validation
dataset microarrays so were omitted from further analysis.
The final group of 36 genes was: ABCA8, ABI3BP, ADAM12,
ADRB1, ANGPT1, ANKRD29, ANKRD44, BCHE, C15orf48,
COL3A1, COL5A1, EGLN3, LIFR, METTL7A, PCM1, PLAU,
PLCB4, RECK, RGCC, RRM2, SEC 14L4, SERPINH1, SFN,
SLIT3, SPP1, TNS1, TOM1L2, TSPAN5, TTYH3, VSIG10,
VCAN, AKR1C1, LRP8, NAMPT, PTGES, SLC27A5 . There
was a very high level of co-ordinated expression between the
36 genes in the training dataset as evidenced by pairwise
correlations ( Fig. 1 A). 
4 S.M. O’Cathail, C.-H. Wu and A. Lewis et al. 
Fig. 1 A) Pairwise correlation heatmap showing the degree of positive (red) and negative (blue) Pearson correlation between the 36 
genes of the NRF2 pathway in the training set. The high positive correlation between a subgroup of genes (bold text) indicate a high 
degree of co-expression. B) Pairwise correlation heatmaps Pearson correlation between the 36 genes of the NRF2 pathway in the 
four validations sets; B = GSE14333; C = GSE39582 RFS; D = GSE39582 OS; E = MRC FOCUS Trial. (For interpretation of the 
references to colour in this figure legend, the reader is referred to the web version of this article.) 
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aVariable selection 
Following PCA, PC1 was indicated to be useful for explain- 
ing the survival outcome by both Akaike and Bayesian infor- 
mation cr iter ia. PC1 in the training set had absolute correla- 
tions > 0.5 with probes that mapped to the following 10 genes: 
VCAN, ADAM12, COL3A1, COL5A1, SERPINH1, RECK, 
PLAU, SPPI, TNS1 and SLIT3 . Due to the high correlation 
of these genes with PC1 in the training set, we hypothesised 
that they were of higher biological relevance for prognosis 
prediction than other NRF2 target genes. This expression pat- 
tern was detected in each of the validation sets ( Fig. 1 B-E). 
A summar y over view of the process for signature derivation 
and training is provided (supplementary figure 2). 
NRF2 activity a biomarker of worse survival 
In stage I/II/III disease, higher NRF2 activity corresponded to 
worse DFS in GSE14333 (HR 2 = 1.551, 95% C.I 1.200–2.004, 
LRT p = 0.0008) and GSE39582 (HR = 1.172, 95% CI 1.008–
1.362, LRT p = 0.0383). Including the 60 cases of stage IV 
disease also available in GSE39582, NRF2 activity was also 
associated with worse OS (HR = 1.240, 95% C.I 1.086–1.416, 
LRT p = 0.001). In the MRC FOCUS tr ial, compr ised of first 2 As NRF2 expression is a continuous variable here, the HR re- 
ported in the text of this section is the HR between the upper and 
lower tertiles of the NRF2 expression. 
s
aine stage IV metastatic patients, NRF2 activity was again as- 
ociated with a worse overall survival (HR = 1.140, 95% C.I 
.035–1.255, LRT p = 0.008). Fig. 2 shows that high activ- 
ty corresponded with worse prognosis for DFS in GSE14333 
nd GSE39582 (panels A and B), and for OS in GSE39582 
nd MRC FOCUS trial (panels C and D). 
In order to assess the relevance of NRF2 activity in rectal 
ancer specifically, and the ability to migrate between RNA ex- 
ression platforms, we performed the analysis on a rectal can- 
er only expression dataset, where all sampled patients re- 
eived neoadjuvant chemoradiotherapy (GSE87211). Higher 
ctivity was associated with worse DFS (HR = 1.431, 95% C.I 
.060–1.933, LRT p = 0.056) but not OS (HR = 1.464, 95% C.I 
.955–2.245; LRT, p = 0.197). Fig. 3 shows that high activity 
orresponded to worse prognosis for DFS. 
RF2 activation provides additional explanatory 
ower to known prognostic variables 
ithin the publicly available datasets there were additional 
ariables that are known prognostic factors. The magnitude 
f their respective effects are summarised in the forest plot 
supplementary figure 3). We used these in a multivari- 
te analysis. In GSE14333, after adjusting for the effect of 
tage and adjuvant chemotherapy, NRF2 activity remained 
 significant predictor of worse DFS (HR 3 = 1.365, 95% 3 See footnote 2. 
5 
Fig. 2 Kaplan-Meier curves and associated risk tables for the primary analysis of three datasets. All show survival outcomes for 
patients with high, intermediate and low (induced by tertiles) of NRF2 metagene expression. A) GSE14333 and B) GSE39582 represents 
early stage I-III patients C) GSE39582 represents stage I-IV patients and C) MRC FOCUS represents stage IV first line metastatic 
patients. For the Kaplan Meier curves, a median cut point was used to binarise NRF2 metagene expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 C.I 1.049–1.776, LRT p = 0.02). Similarly in GSE39582,
the effect of high NRF2 activity corresponds to worse DFS
(HR = 1.168, 95% C.I 1.000–1.363, LRT p = 0.049) after ad-
justing for the effect of stage and mismatch repair status
(MMR). In the latter dataset, NRF2 activity was also signif-
icantly associated with worse OS when adjusting for stage
alone (HR = 1.185, 95% C.I 1.040–1.350, LRT p = 0.01). No
adjusted analysis was carried out for MMR with NRF2 activity
on OS due to the known contrasting effects MMR status hason prognosis in early stage and metastatic disease, which
could lead to model misspecification. 
In the MRC FOCUS trial, prognostic factors within the
dataset were site of the primary tumour (sidedness) and
BRAF V600E mutation. Again, high NRF2 activity corresponded
to worse overall survival (HR = 1.123, 95% C.I 1.020–1.237,
LRT p = 0.0185). In summary, there was systematic evidence
that NRF2 signalling had an effect on DFS and/or OS in all
available datasets ( Table 2 ). 
6 S.M. O’Cathail, C.-H. Wu and A. Lewis et al. 
Fig. 3 Kaplan Meier curves and associated risk tables for the primary analyses of GSE87211. On the left, high NRF2 metagene 
expression is associated with worse disease free survival with persistent separation of the curves. On the right, there was no effect on 
overall survival. For the Kaplan Meier curves, high, intermediate and low (tertiles) of NRF2 expression was used. 
Table 2 Summary table of the Cox proportional hazard model analyses. 
N Analysis Variables HR a (C.I) LRT (p-value) 
Data set 
GSE14333 226 Primary N/A 1.113 
(1.045–1.184) 
0.0008 
Secondary 
Stage Adjuvant 
chemotherapy 
0.0201 
MRC FOCUS 375 Primary N/A 1.033 b 
(1.009–1.245) 
0.008 
Secondary 
Sidedness a BRAF 
V600E mutation ∗
0.0185 
GSE39582 (OS) 570 Primary N/A 1.054 (1.02–1.089) 0.001 
Secondary 
Stage 0.01 
GSE39582 (RFS) 510 Primary N/A 1.04 (1.002–1.08) 0.0383 
Secondary 
Stage 
Mismatch repair 
(MMR) a 
0.049 
GSE87211 (DFS) 189 Primary N/A 1.067 
(1.019–1.2445) 
0.056 
GSE87211 (OS) 189 Primary N/A 0.197 
It shows the numbers of patients included in each analysis, the adjust ing variables where used and the p-value for the Cox model comparison 
(LRT = Likelihood ratio test). 
a Hazard ratio for event per unit increase in expression of NRF2 signature (continuous variable) which is different to HR between the upper 
and lower tertiles. 
b With imputation for missing variables. 
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subtypes (CMS) 
In order to understand how NRF2 activity aligns with the cur- 
rent transcriptomic landscape of colorectal cancer, we ex- 
amined the distribution of the three groups of NRF2 activ- ty level across the four CMS subtypes in the MRC FOCUS 
rial ( Fig. 4 ). While high NRF2 activity can be seen across all 
ubtypes, strikingly CMS 4 showed substantially higher NRF2 
ctivity with no patients in the category of low NRF2 activity. 
y contrast, the majority of patients in CMS 2 or 3 had low 
nd intermediate NRF2 activity. 
7 
Fig. 4 CMS classification was derived for the MRC FOCUS trial dataset. The barplot shows the proportion of high and low NRF2 
metagene expression in each of the four CMS subtypes. CMS 4 was substantially enriched for high NRF2 expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Discussion 
We derived an NRF2 signature to measure activation of the
pathway in colorectal cancer and independently validated it as
a biomarker of poor prognosis across all stages of colorectal
cancer. This is an entirely new biological insight into colorectal
cancer for several reasons. 
To the authors’ knowledge, this is the first demonstra-
tion of NRF2 regulated genes behaving in a co-ordinated
network fashion in CRC, in vivo, and supports our ‘meta-
gene’ approach to represent KEAP1/NRF2 pathway activity.
The high degree of co-expression seen between key genes
VCAN, ADAM12, SPP1, COL3A1, COL5A1, TNS1, SLIT3,
RECK, PLAU and SERPINH1 was consistent with the pre-
dicted behaviour of these genes on the STRING database
[40] (http://string-db.org/; supplementary figure 4). Having
chosen the candidate genes on the basis of NRF2 regulation
in lung cancer strengthens the unbiased nature of the analy-
sis. With the exception of COL3A1, all of the key genes contain
ARE within their promoter region emphasising NRF2’s ability
to directly regulate transcription (supplementary information,
supplementary figure 5). 
Secondly, NRF2 has been shown as a biomarker of poor
prognosis across all stages of colorectal cancer in several
large, independent datasets comprising 1360 patients mak-
ing it one of the largest validation analyses of a transcrip-
tomic biomarker in CRC to date. To place the analysis size
in context, the OS and DFS cohorts used to validate CMS as
a prognostic biomarker were 2129 and 1785 cases respec-
tively [8] . The prognostic effect was maintained when adjust-
ing for known prognostic clinical and molecular factors includ-
ing stage, adjuvant chemotherapy and mismatch repair status
in the non-metastatic setting, and, BRAF V600E mutation and
tumour sidedness in the relapsed setting. The 375 patients
with stage IV metastatic disease have been selected from
a large randomised controlled phase III trial, which makes
the findings more robust against unknown sampling biases.
No other CRC biomarkers other than CMS 4 are consistent
across early and late disease [41] . The enrichment of CMS 4
for NRF2 activity may explain this finding. 
Thirdly, the effect was consistent and robust across the four
datasets in spite of the technical differences in RNA profiling
(three different expression platforms from two different manu-facturers), a combination of FFPE and fresh frozen tissue and
biopsy sizes. 
In spite of the accumulating evidence that NRF2 plays a
significant role in cancer [ 9 , 42 , 43 ] there is remarkably little in-
formation on the prognostic contribution of NRF2 in colorectal
cancer. High levels of NRF2 activity within resected tumours
have been found to be significantly correlated with p53 expres-
sion, Duke’s stage and poor clinical outcomes [44] as well as
tumour size, TNM stage and metastases [45] . Whilst the lat-
ter investigated the association between NRF2 and survival
status, their analysis did not take into account of the various
aspects of time-to-event data, including data censoring or the
concept of time. In addition, it was impossible to directly mea-
sure the prognostic effect of NRF2 in presence of potential
confounders in their analysis framework. 
CMS has defined the current RNA taxonomy of CRC.
The resulting classifications (CMS 1–4) and their respec-
tive prognostic outlooks describe the landscape in which any
novel expression biomarker must be evaluated, especially
as CMS was derived using a network-based clustering ap-
proach, agnostic of underlying biological mechanisms. We
have shown that, although distributed across all four subtypes,
high NRF2 activity is significantly enriched in CMS 4. This
was unexpected. A pr ior i , given that NRF2 is pr imar ily known
as a metabolic pathway and previous data demonstrating co-
occurrence and co-activation with PIK3CA [10] and KRAS mu-
tation [46] , one could have expected enrichment within CMS
3. We would argue therefore that this adds further biologi-
cal insight into the CMS classification and the exact role of
NRF2 in interacting with the CMS 4 subtype warrants fur-
ther study. For example, one of the most enriched biological
processes seen in our NRF2 signature is that of extracellu-
lar matrix (ECM) signalling. Recent proteogenomic work from
squamous cell lung cancer [47] noted that somatic mutations
of NFE2L2/KEAP1 are enriched for transcriptional programs
in ECM similar to the data presented here. Open questions in-
clude whether the cancer cell exerts an outward influence on
the ECM by increasing NRF2 signalling and creating a pro-
tumorigenic environment, or is it an inward effect, with the
ECM altering the biology of the cancer cell. Certainly NRF2 is
increasingly recognised to have a more far reaching effect on
the cancer cell than traditional oxidative stress management
[43] . 
8 S.M. O’Cathail, C.-H. Wu and A. Lewis et al. 
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AThe difference in prognosis between those with high and 
low NRF2 activity could, in part, be due to therapeutic resis- 
tance. Fluorouracil is the main chemotherapy drug used in 
both the adjuvant and metastatic setting, and was the back- 
bone of therapy used in the FOCUS trial. Silencing of NRF2 
signalling has been shown to overcome 5-FU resistance in 
colorectal cancer models in both an in vitro and in vivo set- 
ting [48] . Quantifying the effect of NRF2 activity in therapeutic 
resistance in relation to radiation and chemotherapy in col- 
orectal cancer is ongoing in our laboratory. However, given 
the pluripotent nature of NRF2 it would seem plausible that it 
mediates poor prognosis by influencing multiple mechanisms 
[ 9 , 42 ]. 
Some limitations should be addressed. A low number of 
rectal tumours were analysed and the effect appears sta- 
tistically less marked in the rectal only dataset GSE87211. 
However the relatively smaller number of events (22% and 
13% for DFS and OS respectively) probably mitigated the 
statistical power. It may also due to an artefact of migrating 
between RNA expression platforms, although the signal per- 
sisted. Non-hypermutated colon cancer and rectal cancer are 
not distinguishable at the genomic level [17] so we argue that 
the biology is consistent across all anatomical sites. Having 
accounted for sidedness and MSI where available, high NRF2 
pathway activity remained a poor prognostic feature. Although 
the effect size (HR) may be considered small, the additional 
prognostic and biological information offers genuine clinical 
utility. We used a 36 genes to represent NRF2 pathway acti- 
vation but NRF2 is known to regulate a large number of gene 
targets [49] . There may be an alternative group NRF2 tar- 
gets which could better represent pathway activity in colorec- 
tal cancer. Fundamentally, the primary purpose of our analy- 
sis was to represent NRF2 signalling at a transcriptomic level 
so as to assess and understand its biological relevance to 
colorectal cancer. This is the first rigorous demonstration that 
NRF2 signalling pathway is a biomarker of poor clinical out- 
comes in CRC. 
Conclusions 
For the first time, NRF2 is shown to be a consistent, ro- 
bust prognostic biomarker across all stages of colorectal can- 
cer with additional clinical value to current known prognostic 
biomar kers. Better character isation of its role and relationship 
to other biological factors in colorectal cancer is needed where 
high activity in CMS 4 refines the molecular profile of sub- 
group. The small number of genes needed to quantify NRF2 
activation make it potentially suitable for development as a 
prognostic tool from routine clinical samples. 
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